What are lung cancer?

Targeted drug therapy for lung cancer is divided into the following three situations: 1. For patients with EGFR mutation, gene detection is carried out on patients with lung cancer, that is, exon 18,19,20 and 21 mutations. The drugs that can be used by these patients are divided into three generations. At present, the most commonly used drugs are gefitinib, erlotinib and afatinib of the second generation. After a period of treatment, patients of the second generation will show T790M drug resistance gene. Three generations of drugs should be considered for treatment, that is, AZD-9291. Currently known as osimertinib; 2. Patients with ALK fusion gene rearrangement in lung cancer, the drugs used by these patients are mainly crizotinib, the second generation include alectinib, bugatinib, ROS1, cMET gene mutation can be considered to use crizotinib, some of the latest drugs at present, namely PD-L1 or PD-1;3. Patients without obvious gene mutation can use some drugs that inhibit angiogenesis, bevacizumab, anotinib, etc.